Scholarlink

<p>Despite growing research efforts to prevent hypertensive disorders of pregnancy (HDP) and preeclampsia (PE), the global incidence of HDP continues to rise. This trend parallels the increasing prevalence of chronic hypertension (CH) and obesity among women of reproductive age. HDP is associated with significant maternal and perinatal morbidity, and can contribute to multiple cardiovascular diseases. Therefore, preventing HDP and PE may improve pregnancy outcomes and holds promise for long-term cardiovascular health. Recent studies highlight the use of individualized prevention strategies, including tailored low‑dose aspirin regimens based on maternal pathophysiology. Angiogenic biomarkers such as the soluble fms-like tyrosine kinase-1/ placental growth factor ratio are used clinically to stratify PE risk, enabling the timely identification of high-risk women for targeted intervention. Growing recognition of the preconception and postpartum period as a critical window underscores the need for systematic follow‑up of blood pressure, lifestyle factors, and cardiovascular risk. Emerging evidence supports a life-course approach that views HDP not as a transient pregnancy complication but as a critical sentinel event of future cardiovascular diseases, emphasizing cardiovascular health from preconception to postpartum.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hypertensive disorders of pregnancy and women’s health throughout the life course: an update review 2025–2026

  • 期刊论文

  • 发表日期：

    2026年7月31日

查看全文
  • Marie Yasuda,
  • Asako Mito,
  • Keika Adachi,
  • Kaori Hayashi,
  • Naoko Arata

摘要

Despite growing research efforts to prevent hypertensive disorders of pregnancy (HDP) and preeclampsia (PE), the global incidence of HDP continues to rise. This trend parallels the increasing prevalence of chronic hypertension (CH) and obesity among women of reproductive age. HDP is associated with significant maternal and perinatal morbidity, and can contribute to multiple cardiovascular diseases. Therefore, preventing HDP and PE may improve pregnancy outcomes and holds promise for long-term cardiovascular health. Recent studies highlight the use of individualized prevention strategies, including tailored low‑dose aspirin regimens based on maternal pathophysiology. Angiogenic biomarkers such as the soluble fms-like tyrosine kinase-1/ placental growth factor ratio are used clinically to stratify PE risk, enabling the timely identification of high-risk women for targeted intervention. Growing recognition of the preconception and postpartum period as a critical window underscores the need for systematic follow‑up of blood pressure, lifestyle factors, and cardiovascular risk. Emerging evidence supports a life-course approach that views HDP not as a transient pregnancy complication but as a critical sentinel event of future cardiovascular diseases, emphasizing cardiovascular health from preconception to postpartum.